{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:33:31Z","timestamp":1791905611526,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Identifying patients who may benefit from autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and consolidation strategies. We analyzed data from 12763 patients enrolled in the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), distinguishing those who underwent single (<jats:italic>n<\/jats:italic>\u2009=\u20098736) or tandem ASCT (<jats:italic>n<\/jats:italic>\u2009=\u20094027) from 1998 to 2021. Our findings show that the median age at first ASCT increased over time, while the use of tandem ASCT declined. The shift in treatment practices coincided with higher rates of complete response (CR) post-induction therapy. Significantly improved overall survival and event-free survival over time were observed across all age groups, especially in older patients, but not in patients under 40. Tandem ASCT showed benefits for patients who did not achieve CR after initial ASCT. However, patients with ISS III and renal impairment had poorer outcomes with tandem ASCT. In conclusion, while ASCT remains an important anti-myeloma tool, careful patient selection for tandem ASCT is essential, particularly avoiding its use in patients with ISS III and renal impairment, older age, and those already achieving CR after initial ASCT.<\/jats:p>","DOI":"10.1038\/s41409-024-02490-1","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T10:19:36Z","timestamp":1733393976000},"page":"335-345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma"],"prefix":"10.1038","volume":"60","author":[{"given":"Nora","family":"Grieb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Oeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Ferle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0642-7104","authenticated-orcid":false,"given":"Sarah","family":"Flossdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5552-3149","authenticated-orcid":false,"given":"Sandra","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Salwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Fenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-1676","authenticated-orcid":false,"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":false,"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-285X","authenticated-orcid":false,"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-002X","authenticated-orcid":false,"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Wolfgang","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Teschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kimmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6999-5024","authenticated-orcid":false,"given":"Thomas","family":"Neumuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2805-5973","authenticated-orcid":false,"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"2490_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390:301\u201313.","journal-title":"N Engl J Med"},{"key":"2490_CR2","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936\u201345.","journal-title":"Blood"},{"key":"2490_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt LB, Tichy D, Besemer B, H\u00e4nel M, Raab MS, Mann C, et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol. 2024;42:26\u201337.","journal-title":"J Clin Oncol"},{"key":"2490_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet Lond Engl. 2019;394:29\u201338.","journal-title":"Lancet Lond Engl"},{"key":"2490_CR5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"2490_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433520","volume":"44","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, D\u2019Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F. Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies. Am Soc Clin Oncol Educ Book. 2024;44:e433520.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2490_CR7","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.bbmt.2019.07.004","volume":"25","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, et al. Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the chronic malignancies working party of the european society for blood and marrow transplantation. Biol Blood Marrow Transpl. 2019;25:2134\u201342.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2490_CR8","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495\u2013502.","journal-title":"N Engl J Med"},{"key":"2490_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/bjh.13994","volume":"173","author":"EK Mai","year":"2016","unstructured":"Mai EK, Benner A, Bertsch U, Brossart P, H\u00e4nel A, Kunzmann V, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol. 2016;173:731\u201341.","journal-title":"Br J Haematol"},{"key":"2490_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/annonc\/mdt509","volume":"25","author":"M Merz","year":"2014","unstructured":"Merz M, Neben K, Raab MS, Sauer S, Egerer G, Hundemer M, et al. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol. 2014;25:189\u201395.","journal-title":"Ann Oncol"},{"key":"2490_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.04.004","volume":"62","author":"M Merz","year":"2016","unstructured":"Merz M, Jansen L, Castro FA, Hillengass J, Salwender H, Weisel K, et al. Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. Eur J Cancer. 2016;62:1\u20138.","journal-title":"Eur J Cancer"},{"key":"2490_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clml.2023.08.019","volume":"24","author":"M Steinbach","year":"2024","unstructured":"Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, et al. Multiple myeloma in young patients: a scoping review. Clin Lymphoma Myeloma Leuk. 2024;24:15\u201322.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2490_CR13","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","volume":"7","author":"BK Ragon","year":"2023","unstructured":"Ragon BK, Shah MV, D\u2019Souza A, Estrada-Merly N, Gowda L, George G, et al. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023;7:2746\u201357.","journal-title":"Blood Adv"},{"key":"2490_CR14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Samson D, Reece D, Apperley J, Bj\u00f6rkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115\u201323.","journal-title":"Br J Haematol"},{"key":"2490_CR15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"2490_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BGM Durie","year":"1975","unstructured":"Durie BGM, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842\u201354.","journal-title":"Cancer"},{"key":"2490_CR17","doi-asserted-by":"crossref","unstructured":"Caro J, Al Hadidi S, Usmani S, Yee AJ, Raje N, Davies FE. How to treat high-risk myeloma at diagnosis and relapse. Am Soc Clin Oncol Educ Book. 2021;41:291\u2013309.","DOI":"10.1200\/EDBK_320105"},{"key":"2490_CR18","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Multiple Myeloma, version 4.2024. accessed 27 May 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf."},{"key":"2490_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/bmt.2014.255","volume":"50","author":"HW Auner","year":"2015","unstructured":"Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transpl. 2015;50:209\u201315.","journal-title":"Bone Marrow Transpl"},{"key":"2490_CR20","unstructured":"Facon T, Kumar S, Orlowski RZ, Bahlis NJ, Moreau P, Goldschmidt et al. Final survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA study. Presented at: European Hematology Association Congress; 2024 Jun; EHA Library. P968."},{"key":"2490_CR21","doi-asserted-by":"publisher","unstructured":"Engelhardt M, Kort\u00fcm KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. 2024; https:\/\/doi.org\/10.3324\/haematol.2023.283058 [Early view].","DOI":"10.3324\/haematol.2023.283058"},{"key":"2490_CR22","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1001\/archinte.1996.00440120125014","volume":"156","author":"J Blad\u00e9","year":"1996","unstructured":"Blad\u00e9 J, Kyle RA, Greipp PR. Multiple Myeloma in Patients Younger Than 30 Years: Report of 10 Cases and Review of the Literature. Arch Intern Med. 1996;156:1463\u20138.","journal-title":"Arch Intern Med"},{"key":"2490_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1046\/j.1365-2141.1996.5191061.x","volume":"93","author":"J Blad\u00e9","year":"1996","unstructured":"Blad\u00e9 J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996;93:345\u201351.","journal-title":"Br J Haematol"},{"key":"2490_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3109\/10428199809057562","volume":"30","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma. 1998;30:493\u2013501.","journal-title":"Leuk Lymphoma"},{"key":"2490_CR25","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1080\/10428190600647723","volume":"47","author":"MA Dimopoulos","year":"2006","unstructured":"Dimopoulos MA, Pouli A, Anagnostopoulos A, Repoussis P, Symeonidis A, Terpos E, et al. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma. 2006;47:1553\u20136.","journal-title":"Leuk Lymphoma"},{"key":"2490_CR26","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/bjh.14328","volume":"175","author":"A Jurczyszyn","year":"2016","unstructured":"Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, et al. Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. Br J Haematol. 2016;175:884\u201391.","journal-title":"Br J Haematol"},{"key":"2490_CR27","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3390\/diagnostics14101030","volume":"14","author":"YH Chen","year":"2024","unstructured":"Chen YH, Fogel L, Sun AYE, Yang C, Patel R, Chang WC, et al. The efficacy and safety of tandem transplant versus single stem cell transplant for multiple myeloma patients: a systematic review and meta-analysis. Diagnostics. 2024;14:1030.","journal-title":"Diagnostics"},{"key":"2490_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"2490_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1182\/blood-2018-99-112899","volume":"132","author":"M Cavo","year":"2018","unstructured":"Cavo M, Goldschmidt H, Rosinol L, Pantani L, Zweegman S, Salwender HJ, et al. Double Vs single autologous stem cell transplantation for newly diagnosed multiple myeloma: long-term follow-up (10-Years) analysis of randomized Phase 3 studies. Blood. 2018;132:124.","journal-title":"Blood"},{"key":"2490_CR30","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","volume":"28","author":"B Barlogie","year":"2010","unstructured":"Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 2010;28:1209\u201314.","journal-title":"J Clin Oncol"},{"key":"2490_CR31","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","volume":"25","author":"M Cavo","year":"2007","unstructured":"Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434\u201341.","journal-title":"J Clin Oncol"},{"key":"2490_CR32","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456\u201368.","journal-title":"Lancet Haematol"},{"key":"2490_CR33","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","volume":"38","author":"P Hari","year":"2020","unstructured":"Hari P, Pasquini M, Stadtmauer E, Fraser R, Fei M, Devine S, et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). J Clin Oncol. 2020;38:8506\u20138506.","journal-title":"J Clin Oncol"},{"key":"2490_CR34","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous Transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37:589\u201397.","journal-title":"J Clin Oncol"},{"key":"2490_CR35","doi-asserted-by":"publisher","first-page":"LBA-1","DOI":"10.1182\/blood.V128.22.LBA-1.LBA-1","volume":"128","author":"EA Stadtmauer","year":"2016","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, Knust K, Bashey A, Devine SM, et al. Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 - StaMINA Trial). Blood. 2016;128:LBA-1.","journal-title":"Blood"},{"key":"2490_CR36","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Maintenance after stem-cell transplantation for multiple myeloma. N. Engl J Med. 2012;366:1782\u201391.","journal-title":"N. Engl J Med"},{"key":"2490_CR37","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/bmt.2016.136","volume":"51","author":"K Sweiss","year":"2016","unstructured":"Sweiss K, Patel S, Culos K, Oh A, Rondelli D, Patel P. Melphalan 200\u2009mg\/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival. Bone Marrow Transpl. 2016;51:1337\u201341.","journal-title":"Bone Marrow Transpl"},{"key":"2490_CR38","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114:822\u20139.","journal-title":"Br J Haematol"},{"key":"2490_CR39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/annonc\/mdr276","volume":"23","author":"MA Dimopoulos","year":"2012","unstructured":"Dimopoulos MA, Kastritis E, Michalis E, Tsatalas C, Michael M, Pouli A, et al. The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients\u2019 renal function. Ann Oncol. 2012;23:722\u20139.","journal-title":"Ann Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02490-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02490-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02490-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T19:03:08Z","timestamp":1741633388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02490-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2490"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02490-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods used were performed in accordance with the relevant guidelines and regulations. Data collection and analysis was approved by ethics committees of participating DRST centers and the study was performed according to the declaration of Helsinki. Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}